ArticleScientific reports2025
Overexpression of LINC01354 predicts well prognosis and suppresses esophageal cancer progression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA DLGAP1-AS2 promotes ESCC progression and indicates unfavorable prognosis via the miR-101-3p/EZH2 axis.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Long non-coding RNA (lncRNA) LINC01354 is involved in the progression of some cancer types, but the expression profile and prognostic value of this lncRNA in most tumor types, as well as its role and mechanism in esophageal cancer (ESCA), remain poorly characterized. Here, we identify LINC01354 as a tumor-suppressive lncRNA that inhibits ESCA progression by disrupting cell division signaling. Clinically, a pan-cancer analysis revealed widespread downregulation of LINC01354 in tumors compared to normal specimens, including ESCA and breast cancer (BRCA). Low tumor LINC01354 expression correlated with poor overall survival (OS) in ESCA and BRCA patients. In addition, the low expression of LINC01354 in tumors was validated again by two ESCA cohorts, and LINC01354 showed promising diagnostic potential. Moreover, tissue microarray (TMA) staining based on fluorescence in situ hybridization (FISH) once again confirmed the down-regulation of LINC01354 expression in ESCA. Functionally, enrichment analysis of LINC01354's co-expressed genes indicated its critical role in ESCA cell cycle regulation, and its tumor suppressive effect was verified by an in vivo tumor-bearing mouse model. The inhibition of OE-LINC01354 on ESCA cell-cycle progression was further demonstrated by flow cytometry. Mechanistically, high-depth proteomic profiling revealed that overexpression of LINC01354 alters key cell division regulators, including AURKA, AURKB, BRCA2, CCND1, CDC20, and SOX9, etc. Thus, these findings establish the LINC01354-cell division axis as a novel tumor-suppressive mechanism in ESCA and highlight its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.